Subtype
Meningeal Neoplasm
CI-CAN-00001210Explore in graph →
Non-malignant111 active trials2 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001210Explore in graph →
Clinical trials
275 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06650163 | Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors | recruiting | Phase 1 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07376473 | Psychometric Validation of the MQOL-FR and Descriptive Assessment of Quality of Life in Patients With Meningiomas(MenQOL 2) | not yet recruiting | — | 238 | Centre Hospitalier St AnneOTHER | 0 | Feb 3, 2026 |
| clinicaltrials |
| NCT06592092 | Clinical Study of QH104 Cell Injection for the Treatment of Meningeal Metastases of B7H3+ Solid Tumors | completed | N/A | 3 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06012929 | A Study of ONC201 for Refractory Meningioma | withdrawn | Phase 2 | 0 | University of NebraskaOTHER | 0 | Jan 26, 2026 | clinicaltrials |
| NCT07353229 | 68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma | suspended | Phase 1 | 24 | Thomas Jefferson UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT06752096 | Robot-Assisted Neurovascular Intervention | recruiting | N/A | 10 | Navigantis Inc.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT04113408 | MEningioma Detection Using Non Contrast MRI TecHniquEs(MENTHE) | terminated | — | 315 | Fondation Ophtalmologique Adolphe de RothschildNETWORK | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04113395 | Concordance and Accuracy of MRI in the Detection of Meningiomas: Optimizing Sequences With Low Doses of Gadolinium(CAMOMILLE) | completed | — | 514 | Fondation Ophtalmologique Adolphe de RothschildNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06322342 | Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent | completed | Phase 2 | 18 | Reveal Pharmaceuticals Inc.INDUSTRY | 1 | Dec 26, 2025 | clinicaltrials |
| NCT05305365 | Study Assessing QBS72S For Treating Brain Metastases | active not recruiting | Phase 2 | 21 | Stanford UniversityOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT04541082 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | recruiting | Phase 1 | 102 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT02282917 | Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma | terminated | Early Phase 1 | 7 | Massachusetts Eye and Ear InfirmaryOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07264569 | Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001 | recruiting | Phase 1 / Phase 2 | 42 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 4, 2025 | clinicaltrials |
| NCT01373710 | Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis(HIT) | completed | Phase 1 / Phase 2 | 34 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT04081701 | 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.(DOMINO-START) | recruiting | Phase 4 | 200 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT06930846 | HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)(HOBSCOTCH-CA) | recruiting | N/A | 125 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05800275 | Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease(ETIC-LM) | recruiting | Phase 2 | 30 | UNICANCEROTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT02939300 | Ipilimumab and Nivolumab in Leptomeningeal Metastases | completed | Phase 2 | 18 | Massachusetts General HospitalOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT02162732 | Molecular-Guided Therapy for Childhood Cancer | completed | N/A | 186 | Giselle ShollerOTHER | 2 | Nov 3, 2025 | clinicaltrials |
| NCT05598853 | Intrathecal Double Checkpoint Inhibition(IT-IO) | active not recruiting | Phase 1 | 26 | University of ZurichOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06439420 | CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial(CBT-I in PBT) | completed | Phase 2 | 70 | Virginia Commonwealth UniversityOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT06831461 | Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors(PRIDE) | recruiting | N/A | 156 | Tata Memorial CentreOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07172178 | γδ T-PD-1 Ab Cells in the Treatment of Malignant Meningioma | not yet recruiting | Early Phase 1 | 12 | Nanjing Medical UniversityOTHER | 0 | Sep 15, 2025 | clinicaltrials |
| NCT03501979 | Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD | terminated | Phase 2 | 17 | University of Alabama at BirminghamOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT07092202 | Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases | recruiting | Phase 4 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT04729348 | Pembrolizumab And Lenvatinib In Leptomeningeal Metastases | terminated | Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | terminated | Phase 1 | 40 | Actuate Therapeutics Inc.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06632860 | A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors | recruiting | Early Phase 1 | 40 | Peking Union Medical College HospitalOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07044076 | Translation and Validation of the MQOL Self-questionnaire Into French for Assessing Quality of Life in Patients With Meningiomas(MenQOL) | recruiting | — | 50 | Centre Hospitalier St AnneOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT06036706 | Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:(CANCER-COG) | recruiting | N/A | 108 | Centre Francois BaclesseOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT03567486 | Predictive Factors of Visual Recovery After Paraoptic Tumors Removal(PRONOPTIC) | completed | — | 99 | Fondation Ophtalmologique Adolphe de RothschildNETWORK | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06255249 | Multicenter Evaluation in Patients With MEningiomas of the Response to Treatment With 177LUTEtium-oxodotreotide(MELUTE) | completed | — | 50 | Central Hospital, Nancy, FranceOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT00527410 | A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis(LMD) | terminated | Phase 1 | 9 | BiogenINDUSTRY | 1 | May 30, 2025 | clinicaltrials |
| NCT06809517 | Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis | recruiting | Phase 1 / Phase 2 | 34 | Guangzhou Medical UniversityOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06971406 | High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis(FLAME-1) | not yet recruiting | Phase 2 | 100 | Qiming WangOTHER_GOV | 0 | May 14, 2025 | clinicaltrials |
| NCT05289908 | Intrathecal Pemetrexed for Leptomeningeal Metastasis | completed | Phase 1 / Phase 2 | 34 | The First Hospital of Jilin UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT06718972 | A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China(CLM-tree datab) | recruiting | — | 1,000 | Guangzhou Medical UniversityOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06874426 | The Impact of Endoscopic Endonasal Skull Base Surgery on Olfaction(Endo-Olfact) | recruiting | — | 154 | Universitaire Ziekenhuizen KU LeuvenOTHER | 3 | Apr 23, 2025 | clinicaltrials |
| NCT03095248 | Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors(SEL-TH-1601) | terminated | Phase 2 | 10 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06937268 | DOTATATE PET for Meningioma Radiation Planning(DOTATATE-RT) | not yet recruiting | N/A | 36 | British Columbia Cancer AgencyOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06926803 | A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases | active not recruiting | — | 500 | Qiming WangOTHER_GOV | 1 | Apr 15, 2025 | clinicaltrials |
| NCT04997317 | Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide(PROMENADE) | recruiting | Phase 1 / Phase 2 | 18 | University Hospital, Basel, SwitzerlandOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT05746754 | Proton Cranio-spinal Irradiation for Leptomeningeal Metastasis(CSI ProLong) | recruiting | N/A | 50 | University of AarhusOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT05112549 | Intrathecal Application of PD1 Antibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 26)(IT-PD1) | recruiting | Phase 1 | 46 | University Hospital TuebingenOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06901817 | A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases | recruiting | Phase 2 | 97 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT05034497 | Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases(ReSPECT-LM) | active not recruiting | Phase 1 | 18 | Plus TherapeuticsINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT05793034 | Predictive Factors for Survival in Aggressive Meningiomas(23Men) | recruiting | N/A | 250 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06643000 | Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis | recruiting | N/A | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 6, 2025 | clinicaltrials |
| NCT06861218 | Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases | not yet recruiting | Phase 2 | 42 | Zhejiang Cancer HospitalOTHER | 1 | Mar 6, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Feb 5, 2026source: clinicaltrials